The company initially recalled nine lots of multi-dose  vials of the blood thinner in mid-January after a higher than  usual number of reports of adverse patient reactions. Baxter suspended production of multi-dose vials of the drug  earlier this month while officials search for the cause of four  deaths and hundreds of health problems reported in patients. The U.S. Food and Drug Administration has admitted it never  inspected a Chinese plant that supplies an active ingredient  for Baxter’s heparin before approving it because it mixed up  the name with that of another company. FDA officials have said it is unclear if the Chinese site  is linked to the potential reactions, which include breathing  difficulty, vomiting and rapid drops in blood pressure. The agency previously said it planned to start an  inspection last week of the plant in Changzhou, China, which is  owned by Wisconsin-based Scientific Protein Laboratories LLC  (SPL). FDA officials have said it is agency policy to inspect all  manufacturing sites before granting a drug approval and that  the heparin plant mix-up was an isolated case. “We have assurance from the U.S. Food and Drug  Administration that there is an adequate supply in the market  to meet the demand for these critical and lifesaving drugs,”  Peter Arduini, president of Baxter’s medication delivery  business, said in a statement. Baxter said its recall does not involve heparin premixed  intravenous solutions in bags.
Baxter recalls remaining heparin vial products.